**Eli Lilly’s Orforglipron: A Game-Changer in the Diabetes Treatment market?**
The diabetes treatment market is heating up, with pharmaceutical giant…
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
